Aclaris Therapeutics (ACRS) Cash from Operations (2017 - 2025)
Historic Cash from Operations for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to -$10.9 million.
- Aclaris Therapeutics' Cash from Operations fell 14969.09% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.9 million, marking a year-over-year decrease of 13980.33%. This contributed to the annual value of -$20.1 million for FY2024, which is 7436.96% up from last year.
- According to the latest figures from Q3 2025, Aclaris Therapeutics' Cash from Operations is -$10.9 million, which was down 14969.09% from -$10.0 million recorded in Q2 2025.
- Aclaris Therapeutics' 5-year Cash from Operations high stood at $22.0 million for Q3 2024, and its period low was -$26.4 million during Q1 2023.
- In the last 5 years, Aclaris Therapeutics' Cash from Operations had a median value of -$12.3 million in 2024 and averaged -$13.3 million.
- Per our database at Business Quant, Aclaris Therapeutics' Cash from Operations tumbled by 21414.87% in 2023 and then surged by 18958.75% in 2024.
- Aclaris Therapeutics' Cash from Operations (Quarter) stood at -$17.1 million in 2021, then dropped by 11.95% to -$19.1 million in 2022, then surged by 64.63% to -$6.8 million in 2023, then crashed by 32.2% to -$8.9 million in 2024, then fell by 22.31% to -$10.9 million in 2025.
- Its Cash from Operations was -$10.9 million in Q3 2025, compared to -$10.0 million in Q2 2025 and -$13.1 million in Q1 2025.